This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Prevention of Altitude Illness With Non-steroidal Anti-inflammatory Study (PAINS)

This study has been completed.
Sponsor:
Collaborator:
University of California, San Diego
Information provided by (Responsible Party):
Grant S Lipman, Stanford University
ClinicalTrials.gov Identifier:
NCT01171794
First received: July 27, 2010
Last updated: March 9, 2017
Last verified: March 2017
Results First Received: October 8, 2014  
Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Triple (Participant, Investigator, Outcomes Assessor);   Primary Purpose: Prevention
Condition: Altitude Sickness
Interventions: Drug: Ibuprofen
Drug: Placebo

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Ibuprofen Ibuprofen : 3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
Placebo Visually identical placebo

Participant Flow:   Overall Study
    Ibuprofen   Placebo
STARTED   47   42 
COMPLETED   44   42 
NOT COMPLETED   3   0 



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
Participants meeting all inclusion criteria were analyzed

Reporting Groups
  Description
Ibuprofen Ibuprofen : 3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
Placebo Visually identical placebo
Total Total of all reporting groups

Baseline Measures
   Ibuprofen   Placebo   Total 
Overall Participants Analyzed 
[Units: Participants]
 44   42   86 
Age 
[Units: Participants]
Count of Participants
     
<=18 years      0   0.0%      0   0.0%      0   0.0% 
Between 18 and 65 years      44 100.0%      42 100.0%      86 100.0% 
>=65 years      0   0.0%      0   0.0%      0   0.0% 
Age 
[Units: Years]
Mean (Standard Deviation)
 38.4  (14.5)   34.2  (13.2)   36.6  (13.9) 
Sex: Female, Male 
[Units: Participants]
Count of Participants
     
Female      14  31.8%      14  33.3%      28  32.6% 
Male      30  68.2%      28  66.7%      58  67.4% 


  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Acute Mountain Sickness   [ Time Frame: 2 days ]

2.  Primary:   Acute Mountain Sickness Severity   [ Time Frame: 2 days ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Grant S Lipman ( PI)
Organization: Stanford University School of Medicine
phone: 4152909286
e-mail: lipmangrant@gmail.com



Responsible Party: Grant S Lipman, Stanford University
ClinicalTrials.gov Identifier: NCT01171794     History of Changes
Other Study ID Numbers: SU-12012009-4443
Study First Received: July 27, 2010
Results First Received: October 8, 2014
Last Updated: March 9, 2017